OncoMatch/Clinical Trials/NCT06484777
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Is NCT06484777 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SHR-9539 for for multiple myeloma.
Treatment: SHR-9539 for — This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: T cell redirection therapy (CD-3 redirection technology, CAR-T cell therapy)
Prior Grade 3 or higher CRS (Per ASTCT standards) related to any T cell redirection (eg, CD-3 redirection technology or CAR-T cell therapy)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify